Angela Martínez Valverde
Angela Martínez Valverde
My career has been focused in research on molecular metabolism. During my Doctoral Thesis (UCM, 1988-91), I studied insulin/IGF1 actions in brown adipocytes. During my post-doctoral period at Cancer Research UK (London, 1991-93), I cloned protein kinase D1, a Ser/Thr kinase that subsequent studies revealed its key role in cancer and more recently, in glucose homeostasis. Back to Spain (1994, Assistant Prof. at UCM), I implemented my expertise in signal transduction in unraveling insulin/IGF1 signaling pathways responsible of proliferation/differentiation of brown adipocytes. From 2002 and as a CSIC Senior Scientist (Biochemistry Institute, CSIC/UCM), I explored insulin resistance/sensitivity in the liver, particularly the role of IRS2 and PTP1B, two opposite modulators of insulin action. In 2006 I moved to IIBm Alberto Sols (CSIC/UAM) where I consolidated my leadership as PI and extended my research on the molecular basis of obesity and co-morbidities with a special focus in non-alcoholic fatty liver disease. During the last 10 years I have also investigated in diabetic complications (retinopathy/nephropathy) and drug-induced insulin resistance. In the context of ITN-TREATMENT-H2020, we evaluated the impact of antipsychotics on insulin secretion by beta-cells. These research was funded by competitive national grants (BFU2005, 2008, SAF2009, 2012, 2015, RTI2018), national consortiums (MOIR-CAM, MOIR2-CAM, CIBERDdem) and international grants (EFSD 2011, 2021, MSCA-ITN-TREATMENT) in which I participated as PI.I have collaborated with over 100 relevant national/international researchers as reflected in joint publications, participated in regional (CAM), national (ISCIII, AEI) and international (EUROCONDOR-FP7, ITN-TREATMENT-H2020) consortiums and established contracts with pharmaceutical/biotech companies (Project SL Science to Technology (Spain), Hoffman-La Roche (USA), Medimmune-Astrazeneca (USA, UK), Laboratorios Silanes SL (Mexico DC) and recently Pep2Tango Therapeutics (USA)). These collaborations have been based in testing chemical, genetic and biological tools in preclinical models for metabolic diseases and contributed to a sexenio tecnológico (2009-2014).Scientific results have been presented in national/international meetings. I have also actively participated in activities to communicate with the general public (school visits, researcher’s night, press releases, interviews). Also, I am currently Executive Editor of the Journal of Physiology & Biochemistry, member of the Editorial Boards of BBA Molecular Basis of Disease and Scientific Reports and Member of Spanish Royal Academy of Pharmacy.During my career I have supervised 11 Doctoral Thesis. Since 2012, I have supervised 7 Doctoral Thesis, another will be defended in January 2022 and 3 are ongoing. The doctoral fellows are now working in research (academia), industry and teaching. Just to highlight that my first PhD student holds a Científico Titular (CSIC) position. I have supervised 5 postdoctoral fellows from competitive calls (J de la Cierva, S Borrell) and one of them is now a PI (Nicolas Monardes) at Univ. of Cadiz. The others work in academia or industry. I have also supervised 3 CIBERdem postdoctoral fellows that continue working in research (academia).I have actively participated in grant evaluation (AEI, Israel Scientific Foundation, Diabetes UK, CNRS, etc…) and I collaborated with the AEI in evaluation Committees and as coordinator FOS-BME subarea (2018-21).
91 Trabajos publicados
Compañías
Universidad Complutense de Madrid
No se ha especificado una descripción o un objeto social para esta compañía.
Universidad
Universidad Complutense de Madrid.
91 Trabajos publicados
Attenuation of Olanzapine-Induced Endoplasmic Reticulum Stress Improves Insulin Secretion in Pancreatic Beta Cells.
Tecnologías
obesity
Type 2 diabetes
Metabolic-associated Fatty Liver disease
immunometabolism
liver regeneration
hepatotoxicity diabetic retinopathy diabetic nephropathy brown adipocytes
hepatotoxicity diabetic retinopathy diabetic nephropathy brown adipocytes
Perfil de ORCID
0000-0003-1192-9045